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INTRODUCTION 
 
Age-related hearing loss (ARHL – presbycusis) is the 
number one communication disorder and 
neurodegenerative disease of our aged population; and 
ranks with arthritis and cardiovascular diseases as one 
of the top three chronic medical conditions. We have 
learned much about the functional declines in auditory 
function with age. A loss of hearing sensitivity, 
beginning with the high pitches or frequencies, and the 
inability to understand speech, particularly in the 
presence of background noise, top the list of perceptual 
difficulties characteristic of old age [1]. Similar 
functional deficits in auditory perception occur in most 
aging mammals, including primates and rodents [2-6]. 
However, despite these advances in understanding the 
perceptual and physiological bases of ARHL, there are 
still no FDA-approved drugs on the market to treat the 
permanent hearing loss affecting over 40 million 
Americans, including presbycusis, and this dis-
appointing situation is exacerbated globally. We are just 
reaching the point where our knowledge of the 
structural and molecular changes that occur in the inner 
ear (cochlea) with age, allow us to start formulating 
biomedical interventions to prevent or slow down the 
progression of ARHL.  For example, it has recently 
been shown that knockout mice, deficient in an 
antioxidant protein, show accelerated age-linked loss of 
inner hair cells, which can be treated with an 
antioxidant, N-acetyl-cysteine (NAC) [7].  
 
There are three dominant morphological changes that  
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ABSTRACT 
 
Age-related hearing loss (ARHL) -presbycusis - is the most prevalent neurodegenerative disease and number 
one communication disorder of our aged population; and affects hundreds of millions of people worldwide. Its 
prevalence is close to that of cardiovascular disease and arthritis, and can be a precursor to dementia.  The 
auditory perceptual dysfunction is well understood, but knowledge of the biological bases of ARHL is still 
somewhat lacking. Surprisingly, there are no FDA-approved drugs for treatment. Based on our previous studies 
of human subjects, where we discovered relations between serum aldosterone levels and the severity of ARHL, 
we treated middle age mice with aldosterone, which normally declines with age in all mammals. We found that 
hearing thresholds and suprathreshold responses significantly improved in the aldosterone-treated mice 
compared to the non-treatment group. In terms of cellular and molecular mechanisms underlying this 
therapeutic effect, additional experiments revealed that spiral ganglion cell survival was significantly improved, 
mineralocorticoid receptors were upregulated via post-translational protein modifications, and age-related 
intrinsic and extrinsic apoptotic pathways were blocked by the aldosterone therapy. Taken together, these 
novel findings pave the way for translational drug development towards the first medication to prevent the 
progression of ARHL. 
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occur in the aging cochlea [8, 9]. i) Sensory 
Presbycusis: the loss of sensory hair cells, first outer 
hair cells, followed later by inner hair cells;  ii)Neural 
Presbycusis: declines in the number of spiral ganglion 
cells; where the number of ganglion cells typically 
decreases up to 25% along the entire cochlear duct 
across the lifespan (e.g., [10, 11] and iii) Metabolic 
Presbycusis:  atrophy of the stria vascularis of the 
cochlear lateral wall of scala media.  The latter is linked 
to dysfunction of the Na-K-ATPase and NKCC1 ion 
channel pumps within the stria vascularis. An animal 
model, mice treated with ouabain, an inhibitor of Na-K-
ATPase, involves both metabolic and neural 
presbycusis.  When ouabain is applied to the cochlea it 
leads to Na-K-ATPase-associated apoptosis and 
degeneration of auditory nerve fibers or spiral ganglion 
cells of the cochlea [12].  The preferential loss of the 
low-spontaneous group of spiral ganglion neurons and 
declines of the endocochlear potential (EP) are related 
characteristics of presbycusis [13, 14]. More 
specifically, it has been demonstrated that the 
maintenance of the EP with its high potassium ion 
concentration requires a full complement of NKCC1 
and Na-K-ATP channels in the basolateral membrane of 
the cochlea’s specialized endolymph organ: the stria 
vascularis (SV) and ALD directly regulates protein 
expression  and  activity  of  NKCC1  channels [84]. 
But according to other animal model studies [13, 15, 
16], the EP declines in the cochlea happen in later 
stages of life. Aldosterone (ALD), a steroid hormone 
from the mineralocorticoid family, helps determine the 
levels of potassium (K+) and sodium (Na+) ions, by 
regulating NKCC1 and Na-K-ATPase expression. 
Therefore, ALD is a drug candidate to treat ARHL, 
since it could delay or reverse stria metabolic 
pathogenesis. 
 
Specifically, a noteworthy correlation between ALD 
serum levels and ARHL has been observed [17-20]. In 
addition, ALD levels decrease with age in many species 
including humans and mice [21-27]. As an example, we 
previously discovered that higher serum aldosterone 
(ALD) levels correlate with better hearing in aged 
human subjects [17].  Also, ALD has been shown to 
 
 
Figure 1. ABR threshold shifts (dB) for treated and untreated (control) subject groups following 60 and 120 days of 
treatment. 12 kHz (a), 24 kHz (b), 32 kHz (c) and 36 kHz (d).  Mean (±SEM) frequency-specific ABR threshold shifts in the treatment 
group (n = 5) on days 60 and 120 compared to the control group (n=5) values, showed improved hearing sensitivity for all four test 
frequencies, with the greatest benefit at the higher frequencies. “0” on the ordinate represents the baseline (pre-treatment) ABR 
thresholds.  So, negative threshold shifts represent improvements in hearing with time in the ALD treatment group, while positive 
shifts indicate age-related ABR threshold elevations in the control group. (e) ABR audiogram data upon which 1a – 1d are based.  
Top: Very little change in auditory sensitivity occurs in the ALD treated mice.  Bottom: The control mice show typical age-related 
hearing loss threshold elevations over the 4-month treatment period. Graphs show means (±SEM); solid line is the pre-treatment 
baseline ABR audiogram; the dotted line is for 60 days, and the dashed line is for 120 days of treatment.  ANOVA: +p<0.05 for 60 
days; *p<0.05 for 120 days; **p<0.01 for 120 days, ****p<0.0001 for 120 days. 
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influence hearing, with oral administration reversing 
autoimmune hearing loss in mice, while spironolactone 
(an aldosterone antagonist) blocked this effect [18-20].  
In light of these previous findings, in the present 
investigation we test the hypothesis that ALD may be 
beneficial for the aging auditory system through 
mechanisms involving improved hearing, cochlear cell 
preservation and mineralocorticoid receptor (MCR) 
upregulation. Part of the rationale is that normal 
activation of MCRs in neural systems leads to 
maintenance of neuronal function and survival (e.g., 
[28]). ALD-MCR-mediated effects are often 
independent of agonist ligands, such as in transport 
epithelial cells of the renal tubule, but in neuronal 
systems, such as hippocampal neurons, it is ligand-
dependent [29, 28, 30, 31]. In sum, spiral ganglion 
neurons and SV cells could be regulated by ALD to 
modulate cell survival. The present article reports a 
series of experiments that investigate how ALD is 
associated with cochlear presbycusis and its possible 
roles in delaying or preventing age-related hearing 
impairment.  These studies not only provide novel 
insights into the molecular mechanisms underlying the 
regulation of spiral ganglion and SV cell survival with 
age, but could also lead to the development of novel 
therapeutic strategies for the prevention and treatment 
of ARHL, affecting many millions of people 
worldwide. 
 
RESULTS 
 
Aldosterone treatments prevent age-related hearing 
threshold elevations and improve hair cell responses 
 
First, standard hearing measurements were made to test 
the hypothesis that ALD may be beneficial for 
preventing or delaying age changes in the auditory 
system. The ALD pellet implantation was started at age 
17 months, and lasted for 4 months. Long-term ALD 
treatment effects on peripheral hearing were assessed in 
 
 
Figure 2. ABR Peak 1 amplitude changes (µV) as a function of sound intensity, for treated and untreated 
(control) subject groups, following 60 and 120 days of treatment. 12 kHz (a), 24 kHz (b), 32 kHz (c) and 36 kHz (d).  
Note that the ALD treatment ABR levels tend to be above the control levels at 60 and 120 days of treatment, especially at the 
higher intensities, and for 12 and 24 kHz.  Also, the control levels at the 120 day time point tend to be the lowest of all, due to 
the normal progression of age-related hearing loss.  Quantification of these relative improvements in the ALD treatment 
groups for 80 dB SPL are given in the next Figure. Error bars are SEM. 
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mice by computing the ABR threshold shifts at 12, 24, 
32 and 36 kHz and suprathreshold sound coding was 
measured with ABR peak amplitude intensity functions. 
Threshold improvements due to the ALD treatments 
were discovered at all frequencies with statistically 
significant improvements found when comparing the 
treated group to the non-treated control group (Figs. 1a-
e). These data indicate that the maximum therapeutic 
effect is in the cochlear base, where ARHL typically 
exerts its maximal effects, with smaller improvements 
in the low frequency, apical region. In addition, ABR 
peak I amplitudes were found to be reduced at high 
intensities in the aging control group, but after long-
term ALD treatment amplitudes were significantly 
increased, as displayed in Figures 2 and 3. Specifically, 
the increase in P1 amplitude from baseline controls is 
shown as a function of the intensity of the tone burst 
stimulus for 12, 24, 32 and 36 kHz, panels 2a-d, 
respectively. Improvements in threshold and 
suprathreshold benefits of the ALD were manifested at 
60 days and became more prominent at 120 days of 
treatment, as shown for 80 dB in Figure 3 for all test 
frequencies, i.e., the ALD-treated ABR suprathreshold 
responses are higher than the controls. Also note that 
the treatments actually improved the ABR thresholds 
relative to the baseline thresholds that were measured 
just prior to the beginning of the treatments (baseline = 
0 for the Figs. 1a-d ordinates; a negative shift indicates 
threshold improvements over the course of the 
treatments). 
 
Consistent with Schuknecht’s classification scheme 
presented above ([8, 9]), ARHL in the CBA/CaJ mouse 
involves both hair cell and spiral ganglion neuron loss. 
Therefore, we made initial observations about the status 
of the outer hair cell system, by measuring distortion 
 
Figure 3. ABR Peak 1 amplitude changes (µV) at 80 dB SPL, for treated and untreated (control) subject groups, 
following 60 and 120 days of treatment. 12 kHz (a), 24 kHz (b), 32 kHz (c) and 36 kHz (d).  Box plots (median, 1st & 3rd 
quartiles, whiskers: minimum & maximum) of frequency-specific ABR P1 amplitude changes in the treatment group (n = 5) on 
days 60 and 120 compared to the control group (n=5) values, showed improved hearing, i.e., increased ABR amplitudes, for all 
four test frequencies, with the greater benefits at the higher intensities. “0” on the ordinate represents the baseline (pre-
treatment) ABR amplitude levels.  So, positive shifts represent increased excitatory drive with time in the ALD treatment group, 
while negative shifts indicate age-related ABR level decreases in the control group. ANOVA: *p<0.05; error bars are SEM. 
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product otoacoustic emissions (DPOAEs) before and 
after ALD therapy. The results indicated an 
improvement in DPOAE thresholds in 21 month old 
mice with 60 day ALD treatments (Fig. 4). Based on 
these data, it appears that extended ALD treatments will 
significantly retard certain aspects of the aging process 
on hair cell loss; a finding worthy of more extensive 
investigation in subsequent studies. 
 
Serum aldosterone levels increased into the normal 
range in old mice with aldosterone therapy 
 
Our preliminary findings in middle age CBA/CaJ mice 
provided an appropriate dosage for the longitudinal 
studies reported here [32]. In untreated aging mice, age-
related declines of nearly 50% in serum ALD levels 
occur as compared to young adult mice (details 
presented in Fig. 5). However following treatments, 
serum ALD levels rose to near the normal range, very 
close to that of the young adult comparison group (Fig. 
5). As we report in our companion article [33], ALD 
treatments did not elevate blood pressure; i.e., mean 
systolic (~120 mm Hg) and diastolic (~85 mm Hg) 
pressures remained stable relative to the baseline, and 
over the treatment periods of 60 and 120 days in both 
the control and treated groups. These results indicate 
that long-term ALD treatment does not induce a 
potential negative side effect, using the therapeutic 
dosing regimen of the present study. 
 
Aldosterone rescues age-related spiral ganglion cell 
loss 
 
Interactions between improvements in hearing due to 
 
 
Figure 4.  DPOAE amplitudes and thresholds for treated and untreated (control) subject groups, following 60 and 120 
days of treatment. (a) Amplitudes for the ALD (top) and Control (bottom) groups are similar to each other, and do not change 
systematically during the treatment period.  (b) The DPOAE thresholds show improvement at the higher frequencies for the ALD 
treatment group at 60 days (top), but not for the Control group (bottom). Graphs show means (±SEM).  ANOVA: *p<0.05; **p<0.01, 
***p<0.001, ****p<0.0001. 
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the ALD treatments and spiral ganglion neuron density 
were explored. Specifically, the spiral ganglion cell 
numbers in middle-age treated and control mice were 
compared to that of the untreated young adults. To 
accomplish this, cochlear cross sections were subjected 
to H&E staining and spiral ganglion cell counts were 
made for each cochlear turn (Fig. 6a). Mean cell 
counts/10,000 μm2 significantly decreased in the 
untreated middle-age mice (Figs. 6b), compared to the 
young adult mice. However, following long-term ALD 
treatment there was a noteworthy increase in the 
number of surviving spiral ganglion neurons, relative to 
age-matched controls, indicating a therapeutic effect at 
the level of the modiolus. 
 
Functional hearing preservation with aldosterone 
correlates with spiral ganglion cell rescue 
 
In order to test for co-localization of spiral ganglion 
neuron rescue with frequency-specific hearing 
improvements following ALD treatments, the murine 
cochlear place-frequency map derived by Muller was 
utilized [34]. Müller and colleagues determined the 
cochlear location of physiologically characterized 
auditory nerve fibers along the cochlear partition and 
then mapped the location with best frequency [34, 35]. 
For example, a best frequency of 19.6 kHz was 
localized to a position 50.2% from the cochlear base, 
while 40.5 kHz is 18% from the basal end of the 
cochlea. In the present study, histological confirmation 
of the location of spiral ganglion neurons was correlated 
to ABR thresholds data. Specifically, relations between 
spiral ganglion neuron loss and ABR threshold shifts at 
24 and 36 kHz were examined, and the results revealed 
a positive correlation between spiral ganglion neuron 
(SGN) density and ABR threshold shifts following 120 
days of treatment with ALD: for 24 kHz vs upper basal 
SGN, r2 = 0.48, p = 0.027 (Fig. 6c, top); and for 36 kHz 
vs lower basal SGN, r2 = 0.72, p=0.002 (Fig. 6c, 
bottom). The rescue of SGNs provides anatomical 
confirmation that ALD has a protective effect on SGN 
survival with age and provides a basis for the 
maintenance of high frequency hearing ability. 
 
Mineralocorticoid receptors are expressed in the 
cochlea 
 
Aldosterone is known to exert its physiological effects 
through the activation of mineralocorticoid receptors 
(MCRs). In general, MCRs are involved in the 
maintenance of cellular and structural integrity of 
neurons required for normal cognition, behavior and 
endocrine control [36]. Furthermore, MCRs are 
important for neuronal survival in the rat hippocampus, 
and increased survival of rat primary cortical neurons in 
response to mild stressors [28]. MCRs also improve 
survival of hippocampus neurons after transient global 
ischemia, and play regulatory roles in many other 
tissues [37, 38]. We hypothesized that like central 
nervous system neurons, SGNs would also be under the 
influence of the aldosterone-MCR axis. To test this, the 
expression patterns of MCRs in SGN cell bodies were 
examined. As a positive control RNA from mouse heart 
and liver were utilized, as MCRs are known to be 
abundant in cardiac and liver tissue [39-41]. A sample 
from the mouse heart without reverse transcription was 
used as negative control condition. Moderate MCR gene 
(Fig. 7, top) and protein (Fig. 7, bottom) expression was 
observed in the SGNs of young adults, and in stria 
vascularis cell bodies (not shown). More intense 
staining was observed in other cochlear structures such 
as the tectorial membrane. 
 
Aldosterone reverses the down-regulation of MCRs 
with age by blocking posttranslational modifications 
 
MCR-mediated effects are largely independent of 
agonist ligands in transport epithelia such as the renal 
tubules, however this is not the case in neuronal 
systems, such as the brain, including the hippocampus, 
where modulation of the presence of MCR is ligand 
dependent [29, 30, 31]. As shown in Figure 8a, mRNA 
expression of MCRs in spiral ganglion neurons was 
detected, but there was no difference in the gene 
expression levels among all the subject groups. In 
contrast, both proteomics methodologies employed 
(immunohistochemistry, western blot), revealed that the 
MCR protein expression is down-regulated in spiral 
ganglion neurons of middle aged mice compared to 
young adults (Figs. 8b, 8c). However, following 4 
months of ALD treatment a 2-fold up-regulation of 
 
Figure 5. The serum aldosterone levels from young 
adult and middle age CBA/CaJ mice with or without the 
aldosterone treatment, 0.0016 mg/day continuous 
release, subcutaneous pellet through 120 days. The 
systemic aldosterone treatment restored serum levels to near 
the normal range for young adults. Graphs show means 
(±SEM). ANOVA:  ****p<0.0001. 
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MCR expression occurred. These results indicate that 
age-related down-regulation of MCRs in spiral ganglion 
cells involves a post-transcriptional modification that 
can be prevented by ALD hormone therapy initiated in 
middle age. 
 
Molecular mechanisms for age-linked spiral 
ganglion neuron death 
 
One known mechanism by which MCRs can influence 
neuron survival in the brain is by inhibiting apoptosis 
[42]. In addition, we have previously identified age-
linked upregulation of apoptotic pathways in the 
CBA/CaJ cochlea [43]. The signaling cascades inducing 
apoptosis in mammalian cells can be divided into two 
pathways: either mitochondrial (intrinsic) or death 
receptor (extrinsic) [44-46]. However, the extent to 
which apoptosis is a key mechanism for age-related 
spiral ganglion cell loss is not known. For instance, a 
previous investigation found no effects of Bax-/- or Bcl-
2 over-expression on age-related loss of spiral ganglion 
neurons [47]. Based upon this study, and our previous 
work on cochlear apoptosis in CBA/CaJ mice [43], we 
further investigated the role that apoptotic pathways 
play in age-related spiral ganglion neuron loss. 
Pathways involved that may be independent of Bax/Bcl-
 
 
Figure 6.  Hematoxylin/eosin (H&E) staining patterns in the cochlea reveal spiral ganglion neuron (SGN) loss with age, 
and rescue with aldosterone hormone treatments. (a) Cross section of the complete CBA mouse cochlea showing all turns: 
Section-thickness is 5 µm, Magnification: 2.5 X 1.6. All cochlear turns are distinguishable as: upper apical, upper basal, lower apical 
and lower basal. The cell number measurements of SGNs included all turns:  (b) SGN cell count densities were measured by light 
microscopy for the young adult (left panel) and middle-aged mice with (right panel) and without (middle panel) aldosterone 
treatments; Magnification: 20 X 1.6. Right panels show bar graphs representing the SGN cell density. Mean ±SEM for each subject 
group.   *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.  (c) Statistically significant correlations between SGN density and 24 and 36 
kHz ABR threshold shifts indicate that a reduction in the number of SGNs are associated with poorer hearing (higher ABR thresholds). 
Open points are for ALD treated animals, and filled points are for the controls who are undergoing normal age-related hearing loss.  
According to the physiological place-frequency map of the mouse cochlea (see text), 24 and 36 kHz are located at upper and lower 
basal turns of the cochlea, which correspond to the cochlear locations with the most cell density loss with age in CBA/CaJ mice. 
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2 pathways [46], are presented in Figure 9a. The 
intrinsic and extrinsic pathways, both at the end point of 
the execution phase, are often considered key 
components of the final apoptotic pathway. It is the 
activation of the execution caspases that begins this 
terminal phase of apoptosis. Execution caspases activate 
cytoplasmic endonucleases, which degrade nuclear 
material, and involve proteases that break down nuclear 
and cytoskeletal proteins.  Caspase-3 is often considered 
to be the most important of the executioner caspases 
and is activated by any of the initiator caspases [48, 46]. 
We assayed the expression of Caspase-3 in spiral 
ganglion neurons to determine its involvement in 
ARHL. As shown in Figure 9b, Caspase-3 expression 
increased in middle-age spiral ganglion neurons 
compared to young adults, and the induction of cleaved 
caspase-3, which is the activated form of caspase-3, was 
also observed (Fig. 9b). Relevant to the activation of 
either intrinsic or extrinsic pathways,  the apoptotic 
intrinsic inducer Bax was found to be upregulated, and 
the survivor factor Bcl-2 (likely involving inhibition of 
mitochondrial cytochrome c release) was down-
regulated with aging in spiral ganglion neurons (Fig. 
9c). These data suggest that the apoptotic intrinsic 
pathway is activated in cochlear aging. In addition, 
extrinsic factor Caspase-8 (a hallmark of apoptotic 
extrinsic pathways such as caspase-1, 3, 6, 7 chain 
reactions), activated two caspase-8 fragments, p18 and 
p43, in spiral ganglion neurons of middle age mice 
compared to the young adult group.  In addition, 
following the 4 months of ALD treatment Caspase-3 
expression levels were significantly reduced, and 
simultaneously the induction of cleaved caspase-3 
disappeared (Fig. 9b, Western blot). Also, the declines 
of Bcl-2 with age were reversed, and the levels of 
activated Bax and caspase-8 were decreased with the 
ALD treatment (Fig. 9c). So together, these data 
indicate that the extrinsic and intrinsic apoptotic 
pathways are upregulated with age in spiral ganglion 
neurons, and ALD can be a double-edged intervention 
to block age-related apoptosis. These studies support the 
hypothesis that age-related cochlear neuron loss 
involves both extrinsic and intrinsic apoptotic pathways. 
 
Additionally, apoptotic DNA fragmentation is a key 
feature of apoptosis, characterized by the activation of 
endogenous endonucleases with subsequent cleavage of 
chromatin DNA into internucleosomal fragments of 
roughly 180 base pairs (bp) and multiples thereof. DNA 
fragmentation can be detected via DNA laddering and 
the TUNEL assay. However, nucleosomal ladders have 
only been clearly demonstrated when vast numbers of 
cells die synchronously, so asynchronous cell death 
with subtle DNA fragmentation cannot be routinely 
detected by DNA fragmentation assays [49]. Therefore, 
we used a highly sensitive method, ligation-mediated 
polymerase chain reactions (LMPCR), to amplify the 
nucleosomal ladder of SGNs from young and middle-
aged mice [49, 50, 51, 52-55]. Typically, DNA 
fragments have 5'-phosphorylated blunt ends, which can 
be ligated to dephosphorylated adaptors composed of a 
12-mer and a 27-mer. When the mixture of ligated DNA 
fragments is heated, the 12-mer is released. Next, the 5' 
protruding ends are filled in by a thermostable DNA 
polymerase. The 27-mer then serves as a primer in a 
PCR in which the fragments with adaptors on both ends 
are exponentially amplified. The resulting nucleosomal 
ladder can be easily visualized on an agarose/EtBr gel. 
The observed increase in apoptosis in aged spiral 
ganglion neurons was demonstrated by the elevated 
levels of cleaved genomic DNA by formation of a DNA 
ladder (Fig 9c), but ALD treatment for 4 months 
inhibits the aging induced DNA fragmentation ladder in 
spiral ganglion neurons 
 
DISCUSSION 
 
Consistent with the success of the therapeutic 
intervention administered to middle age animals to slow 
down the progression of ARHL in the present report, 
there is growing evidence that key aspects of ARHL 
emerge in middle age. For example, the auditory 
 
 
Figure 7. Mineralocorticoid receptor (MCR) expression 
and distribution in the cochlea of the young adult (3 
mon) CBA/CaJ mouse. (a) Multiplex RT-PCR was performed 
as described in the text. This experiment includes the absence 
of reverse transcription (control lane -RT). The mRNA 
expression of MCRs in tissue from heart (H), muscle (M) and 
spiral ganglion neurons (SG), where the product of RT-PCR is 
about 245 bp. -RT- reverse transcription without primers (as 
the negative control). L-Ladder: DNA molecular weight 
markers. (b) The protein expression of MCRs in SG was 
detected using immunohistochemistry staining (brown color, 
MCR+). A portion of the limbus is shown as a cochlear region 
not displaying significant MCR staining (MCR-). 
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efferent feedback system, known as the medial 
olivocochlear bundle, arises from the superior olivary 
complex of the brainstem and provides efferent control 
to the cochlear outer hair cells, providing a gain control 
mechanism for regulating hearing sensitivity in the 
presence of suprathreshold stimuli and background 
noise conditions [56, 57]. We previously discovered in 
middle-aged humans [58] and middle-aged mice [59-
61], that this feedback loop starts to show significant 
functional declines. In addition, prevailing evidence 
indicates that auditory spectral and temporal processing 
deficits start to manifest themselves in middle age 
humans [62-64], and in animal models starting in 
middle age [65, 66]. Additional investigations, across 
the lifespan of CBA/CaJ mice, including young adult 
(up to 10 mon), middle age (10-20 mon) and old age 
(20- 30 mon) [67, 68], provide additional instances of 
relevant auditory functional deficits that start in middle-
aged mice, including elevations in ABR thresholds, 
especially at the higher frequencies. 
 
There is also evidence to support possible roles of 
apoptosis in the aging cochlea, as has come from reports 
of the association between aging changes in apoptotic 
gene expression [43] and alterations in the expression of 
apoptosis-related proteins [69, 70]. For example, 
  
Figure 8.  MCR presence in spiral ganglion neurons from young adult (3 mon), and aged (21 mon) control mice and 
those which were treated aldosterone (ALD) from 17 months up to 21 month. (a) mRNA gene expression of MCRs in young 
adult, aged mice and aged mice with ALD treatment were all of similar magnitudes. 3 mon: Modiolar samples from young adult mice, 
21 mon: Modiolar samples from aged mice.   L-Ladder: DNA molecular weight. (b) The MCR protein expression level was determined 
by densitometry analysis (MetaMorph Image Analysis System) of immunocytochemistry sections; upper panels show representative 
sections for the MCR antibody staining. The insets in the upper panels represent a typical MCR-DAB stained spiral ganglion neuron. 
The lower panel presents a bar graph summarizing the relative densities from densitometry measurements: Mean ± SEM for each 
group. (c) MCR protein expression in spiral ganglion neurons shown by western blots of modiolar tissue samples. The expression level 
is reported relative to the expression of beta-actin as the loading control. For both measures of protein expression (b and c), the ALD 
treatments helped rescue the age-related declines in MCR protein expression.  Statistical significance: *p< 0.05, **p<0.01, 
***p<0.005, ****p<0.001. 
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investigation of a role for apoptosis in hair cell and 
SGN loss with age has occurred using the terminal 
deoxynucleotidyl transferase-mediated dUTP-biotin 
nick end-labeling (TUNEL) method, and the presence 
of DNA fragmentation in hair cells and SGNs during 
aging has been found [71-73]. However, it is known 
that TUNEL is not quite specific for apoptotic cells  
even though it is a very popular method to detect 
apoptosis, as nuclear fragments from necrotic or 
autolytic cells may also be TUNEL-positive.  The 
occurrence of false positive staining has been noticed 
for several conditions such as inappropriate fixation and 
unmasking after formalin fixation and paraffin 
embedding through protease addition [74-76].  More 
recently, the internucleosomal DNA cleavage pattern 
has been demonstrated as a specific feature of 
apoptosis, and has become a recognized marker of 
programmed cell death. However, in conditions in 
which only a small percentage of cells are apoptotic, or 
in which apoptosis is occurring asynchronously, 
genomic DNA ladders may appear as a smear and not 
be definitive. So, the ligation-mediated PCR is an 
 
 
Figure 9.  Apoptotic biomarker expression levels in modiolar tissue samples from young adult (2-3 mon), middle-
aged (20-21 mon) ALD-treated and untreated CBA/CaJ mice. Panel (a) shows the key molecules (Bcl-2, Bax, caspase 3 & 8) 
for the apoptotic pathways being investigated. (b) Cleaved caspase-3 protein expression is elevated in middle age controls, but 
reduced in ALD-treated mice. Since caspase-3 is an executor of apoptosis and a common factor of the intrinsic and extrinsic 
pathways, its upregulation can induce apoptosis.   Note: the antibody utilized here also recognizes the cleaved caspase-3 to a 
lesser degree.  Statistical differences are relative to the young adult levels. (c) To further assess age-related changes in the 
apoptotic pathways, the extrinsic factor, caspase-8, and intrinsic factors, Bcl-2 and Bax, were examined using western blots (WB).  
All three biomarkers were activated as shown: caspase-8 cleavages including p43 and p18 were enhanced in the middle age mice 
compared to the young adults, but reduced in ALD-treated mice. Bax was increased, but Bcl-2 was decreased with aging in SGNs, 
and ALD treatment inhibited the age-related changes of both molecules.  Lastly, the DNA ladder detected in aging SGNs, but ALD 
treatment prevented the genomic DNA to be digested by endonucleases, L-Ladder: DNA molecular weight. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
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option to amplify the nucleosomal ladder, increasing the 
visualization.  Figure 10 summarizes the molecular 
cascade in which aging promotes the onset of apoptosis 
in SGNs, including both intrinsic (Bcl-2, Bax) and 
extrinsic (Caspases-dependent) pathways. However, the 
age-related involvement of apoptotic pathways in SGN 
cell loss in the aged cochlea is still not completely 
understood. For example, loss of hair cells and SGNs is 
still found in young adult mice lacking caspase-3, a key 
downstream caspase in the apoptotic cascade. So, it is 
likely that activated caspase-3 may be sufficient but not 
essential for the death of hair cells and SGNs [77]. For 
example, using both Bax knockout (Bax−/−) and Bcl-2 
over-expressing mice, previous investigators failed to 
find any significant difference in age-related loss of hair 
cells and SGNs between controls and transgenic mice 
[47]. Taken together, the results of the present report 
and previous studies suggest that age-related hearing 
loss does not occur through an apoptotic pathway 
involving key members of the Bcl-2 family. However, it 
is likely that aging initiates apoptosis processing in an 
inner loop network, so inhibiting several key molecules, 
but not all apoptotic pathways. According to the 
findings of the present report, ALD interferes with the 
ageing process involving several molecules, such as 
Bcl-2 induction, and Bax and caspase pathway 
inhibition.  Lastly, since mitochondrial activity is 
involved in these apoptotic pathways (Fig. 10), changes 
in oxidative stress and their therapeutic regulation may 
play a role here in modulating age-related hearing 
conditions [78].  In sum, these findings suggest that 
developing a biomedical intervention to be administered 
in middle age, would be an optimal time point to 
prevent or decrease salient features of ARHL. 
 
In closing, the auditory system provides a unique 
window into the neurobiological changes that occur in 
the aging nervous system. Hearing and auditory 
perceptual capabilities can be tested quickly and 
quantitatively, so that correlations between sensory 
perception and anatomical and molecular biomarkers 
can be compared quantitatively, as was accomplished in 
the current investigation. For example, in the present 
study we showed that ALD treatments over a 4-month 
period could help preserve hearing in aging mice, and 
identified several key biomarkers, including 
mineralocorticoid receptors on SGNs, which are related 
to both apoptotic intrinsic and extrinsic pathways. So 
the present investigation is an essential pre-clinical step 
forward. Verification of these findings in another 
mammalian species, and exploration of the possible 
therapeutic effects on additional biological mechanisms 
of ARHL, to justify trials in humans will be additional 
necessary steps to move towards FDA clinical trials. 
Translationally, it may be that ALD combined with 
other critical compounds could be given systemically 
(orally, time-release skin patch), if there are no side 
effects, or have beneficial systemic effects for an aging 
mammal. Alternatively, if side effects are detrimental 
(which was not the case in the current study, e.g., stable 
blood pressure throughout the treatment period), a 
medicine to improve hearing in the elderly could be 
given locally to the inner ear via microsystem delivery 
techniques that we are currently developing [79-82], or 
via transtympanic injections into the middle ear near the 
round window, perhaps using nanoparticles as drug 
carrying vehicles.  
 
CONCLUSION 
 
The findings of the current report indicate that ALD, a 
naturally occurring hormone that declines with age, 
when prescribed in middle age, can prevent or slow 
 
Figure 10. Schematic of the potential molecular 
pathways which illustrate the main findings of the 
present investigation, suggesting that ALD interferes 
with apoptotic pathways for aging in spiral ganglion 
neurons. Aging processes triggers Bcl-2 inhibition and Bax 
activation, which are key factors in intrinsic pathways, and 
promotes the caspase-dependent extrinsic pathway. Aldo-
sterone, through the activation of cochlear mineralocorticoid 
receptors, blocks apoptotic processing induced by aging, i.e., 
Bcl-2 is increased and Bax is decreased to inhibit the intrinsic 
apoptosis induced by aging, Caspase-dependent pathways are 
also inhibited. 
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down some of the key aspects of presbycusis in aging 
mice. Our new results point towards possible cellular 
and molecular mechanisms for this therapeutic effect: 
Upregulation of mineralocorticoid receptors via 
reduction of post-translational protein modifications, 
preservation of hair cells and spiral ganglion cells, and 
partial blocking of apoptotic and cell death pathways. 
These animal model findings pave the way for 
translational medicine development of an FDA 
approved drug to treat presbycusis, which affects 
hundreds of millions of people worldwide. It is likely 
that an approved drug to treat ARHL will be a cocktail 
of two or more therapeutic agents, and based upon the 
discoveries in the current report, ALD will be one of 
those key compounds. 
 
MATERIALS AND METHODS 
 
Subjects 
 
Fifteen CBA/CaJ young adult (2-3 mon) and middle-
aged mice (16-17 mon) served as subjects. Original 
breeding pairs were purchased from Jackson Labs (Bar 
Harbor, ME), and used to provide an in-house source of 
subjects that were housed and maintained in a standard 
husbandry facility of the University of South Florida 
Vivarium. All procedures were compliant with the 
University of South Florida IACUC protocols and all 
federal animal welfare regulations, including the NIH 
Guide for the Care and Use of Laboratory Animals. 
 
Hearing measurements 
 
The ABR and DPOAE testing procedures were similar 
to our previous reports [59, 61, 68].  
 
Auditory brainstem response (ABR) procedures 
 
Middle-aged mice were divided into two groups: 
treatment (N=5) and control (N=5), and had clearly 
visualized, healthy tympanic membranes. Prior to 
recording the auditory brainstem response (ABR) mice 
were anesthetized with a mixture of ketamine/xylazine 
(120 and 10 mg/kg body weight, respectively, IP 
injection). Briefly, ABR sessions were carried out in a 
soundproof acoustic chamber (IAC lined with Sonex), 
with body temperature maintained at 37°C with a 
heating pad. Prior to recording, the stimulus probe was 
placed near the tympanic membrane with the aid of an 
operating microscope. Needle electrodes were inserted 
at the vertex (non-inverted) and in the muscle posterior 
to the left pinna (inverted), with a ground inserted under 
the contralateral pinna. ABR waveforms were evoked 
with 5 msec tone pips (0.5- msec rise-fall times) with a 
cos2 onset envelope, delivered at 21/sec though 
electrostatic speakers (TDT EC1) connected by 4 cm 
tubes to the opening of the external ear canal. The 
response was amplified (10,000 X), filtered (100 Hz–3 
kHz), and averaged using the BioSig (TDT, Gainesville, 
FL) data acquisition system. A total of 200 responses 
were averaged (with stimulus polarity alternated), using 
an ‘artifact reject’ algorithm, whereby response 
waveforms were discarded when peak-to-peak 
amplitude exceeded 7 μV, to prevent contamination by 
muscle activity. Intensity was varied in 5 dB steps 
starting at 80 dB and decreasing to at least 20 dB below 
threshold for a specific test frequency. Each intensity 
was replicated and threshold was defined as the lowest 
intensity at which a response was replicated, as 
determined by two experimenters blind to the 
experimental condition. The recording sessions 
occurred every 2 months after the initial evaluation 
(baseline) for a period of 4 months. 
 
Distortion product otoacoustic emissions (DPOAEs) 
 
Ipsilateral acoustic stimulation and simultaneous 
measurement of DPOAEs were accomplished with the 
Tucker Davis Tech. (TDT) BioSig III system. Stimuli 
were digitally synthesized at 200 kHz using SigGen 
software applications with the ratio of frequency 2 (F2) 
to frequency 1 (F1) constant at 1.25; L1 was equal to 65 
dB sound pressure level (SPL) and L2 was equal to 50 
dB SPL as calibrated in a 0.1-mL coupler simulating the 
mouse ear canal. After synthesis, F1, F2, were each 
passed through an RP2.1 D/A converter to PA5 
programmable attenuators. Following attenuation, the 
signals went to ED1 speaker drivers which fed into the 
EC1 electrostatic loudspeakers coupled to the ear canal 
through short, flexible tubes with rigid plastic tapering 
tips. For DPOAE measurements, resultant ear canal 
sound pressure was recorded with an ER10B+ low-
noise microphone and probe (Etymotic) housed in the 
same coupler as the F1 and F2 speakers. The output of 
the ER10B+ amplifier was put into an MA3 microphone 
amplifier, whose output went to an RP2.1 A/D 
converter for sampling at 200 kHz. A fast Fourier 
transform (FFT) was performed with TDT BioSig 
software on the resultant waveform. The magnitude of 
F1, F2, the 2f1-f2 distortion product, and the noise floor 
of the frequency bins surrounding the 2f1-f2 
components were measured from the FFT. The 
procedure was repeated for geometric mean frequencies 
ranging from 5.6 to 44.8 kHz (eight frequencies per 
octave) to adequately assess the neuroethologically 
functional range of mouse hearing.  
 
Mice were anesthetized with a mixture of ketamine and  
xylazine (120 and 10 mg/kg body weight, respectively) 
by intraperitoneal injection before all experimental 
sessions. All recording sessions were completed in a 
soundproof acoustic chamber (lined with Sonex) with 
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body temperature maintained with a heating pad. Before 
recording, the operating microscope (Zeiss) was used to 
place the stimulus probe and microphone in the test ear 
close to the tympanic membrane. The recording session 
duration was limited by depth of anesthesia, and lasted 
approximately 1 hour per animal. 
 
Aldosterone hormone treatment implantation 
 
After baseline ABR recording at 16-17 months of age, 
while still fully anesthetized, mice were assigned 
randomly to the treatment or control groups; the 
treatment group received implantation injection of a 
custom d-aldosterone pellet: 0.0016 mg/day, 120-day 
release (Innovative Research of America, Sarasota, FL), 
and the control group received the saline placebo, both 
placements were subcutaneous, just behind the 
shoulder. Blood Pressure Measurements: As a measure 
of cardiovascular health, a group of young adult (N=5) 
CBA/CaJ mice, and the middle-aged mice described 
above were placed in a restraining tube to acclimate 
them to having their blood pressure (BP) measured, by 
placing them in a holder for 15 min for 3 consecutive 
days prior to the actual BP measurements (Kent 
Scientific CODA™ tail-cuff system). The animal was 
either placed in the holder by picking up the tail, or the 
animal entered freely. The rear hatch to the holder was 
carefully secured, and care taken to avoid pinching the 
tail or any other body parts while securing the rear 
hatch. The mouse was allowed to rest at least 5-minutes 
to acclimate to the holder. 
 
Serum collection and anatomical tissue preparation 
 
After 4 mon of ALD treatments, the middle-aged and 
young adult mice were exsanguinated via cardiac vessel 
perfusion, with Euthasol® (0.22ml/kg). A thoracotomy 
was performed to gain access to the heart and the 
cardiac vessel was punctured by an 18G sterile 
hypodermic needle. Blood was allowed to free-flow 
from the puncture site and collected with a sterile 
Pasteur pipette, then transferred to an Eppendorf tube in 
a 37oC water bath for 30 min, centrifuged 2000 rpm for 
25 min, and then the serum was taken off and stored at -
80oC. The mouse was then decapitated, and the 
cochleae were quickly removed from the temporal bone 
and transferred into ice-cold DPBS (HyClone Lab Inc., 
Logan, UT) on ice to dissect the modiolus from one of 
the cochlea using a Zeiss stereomicroscope; and then it 
was placed into an Eppendorf tube in dry ice and 
transferred into -80oC in preparation for RT-PCR and 
Western blots. 
 
Immunohistochemistry 
 
The other cochlea was placed in a glass vial with 10 ml 
fresh 4% paraformaldehyde (Thermo Scientific, 
Rockford, IL) in PBS (0.1 M, pH 7.6) overnight at 4oC. 
After fixation, the cochleae were washed 3 X 10 min in 
PBS and then decalcified in 20 ml 10% EDTA 
(ethylenediaminetetraacetic acid, Fisher Scientific, 
Pittsburgh, PA) in PBS at 4oC; the cochleae were 
checked daily until decalcification was complete 
(approximately 1 week). Next, they were washed 3 X 
10 min in PBS, transferred into 10% and 20% sucrose 
(Acros, Geel, Belgium) in PBS for 2 hours each, then 
kept in 30% sucrose in PBS for overnight at 4oC until 
sinking. The cochleae were embedded into degassed 
OCT (Tissue-Tek, Torrance, CA) overnight at 4oC, 
orientated into the cryomold (Tissue-Tek) with OCT 
degassed for 1 hr, and then frozen at -80oC. 
Cryosectioning was performed at 5μm/section, and 
sections were mounted on glass slides. 
 
Hematoxylin and Eosin (H&E) Staining 
Cochlear slides were washed in dH2O for 1 min, and 
then stained for 5 min with the BBC Histo•Perfect™ 
H&E Stain kit (BBC Biochemical, Mt. Vernon, WA). 
Slides were rinsed with dH2O for 1 min, differentiated 
by BBC Acid wash for 1 min, and rinsed with dH2O for 
1 min; then placed into BBC Blueing solution for 30 
sec, and rinsed by dH2O for 1 min. Next, the slides went 
into 70% alcohol for 30 sec, stained with BBC Special 
Eosin II for 1 min, dehydrated with BBC S2*Histo 5 X 
20 sec, and cleared in xylene and coverslipped using a 
permanent mounting media (Fisher Scientific, 
Pittsburgh, PA). Semi-automated cell counts were made 
using the MetaMorph imaging system with a Leica 
DMR microscope, using procedures similar to our 
previous investigations of the mouse aging auditory 
system [61, 68, 83]. 
 
Receptor protein expression measured with 
immunohistochemistry 
 
Mineralocorticoid Receptor (MCR): Cochlear section 
slides were washed in TBS twice for 5 min. They were 
then incubated for 10 min at room temperature in 3% 
H2O2, diluted in methanol, and washed with TBS for 2 
X 5 min. Each section was treated with 100-400 μl 
blocking solution (0.3% triton- X 100 and 5% normal 
goat serum in TBS) for 1 hr at room temperature. Then 
removed from the blocking solution, with the addition 
of 100-400 μl anti-MCR (SC-25709, Santa Cruz 
Biotechnology, Dallas, TX) 1:25 diluted in blocking 
solution. Next, incubated overnight at 4oC. In the 
morning, the slides were washed in TBS 3 X 5 min, 
then Covered with 1-3 drops of signal stain boost IHC 
detection reagent (HRP, Rabbit, Cell Signaling, 
Danvers, MA) and incubated in a humidified chamber 
for 30 min at room temperature. Then, 3 X 5 min 
washes with TBS. Then 100-400 μl DAB was placed on 
www.aging-us.com 2094 AGING (Albany NY) 
each slide for intensification, then the slides were 
immersed in dH2O, and washed 2 X 5 min, followed by 
dehydration and coverslipping. 
 
ELISA for measuring serum aldosterone levels 
 
50 μl serum samples were processed using an 
aldosterone ELISA kit (#1875, Alpha Diagnostic Int., 
San Antonio, TX) according to the manufacturers’ 
protocol. An absorbance microplate reader 
(ELx800TM) and microplate data collection & analysis 
software (Gen5TM, BioTek, Winooski, VT) were used 
for data collection, with data reported as pg/ml. The 
expected young adult range for mice is 25-315 pg/ml. 
 
Gene expression - RT-PCR 
 
Semi-quantitative RT-PCR analysis was performed as 
previously described [84, 85]. Briefly, total RNA was 
extracted using the RNAeasy Mini Kit (Qiagen, 
Valencia, CA). Tissue and cells were vortexed for 1 min 
to shear genomic DNA before loading onto the RNeasy 
mini columns, and then eluted in a minimum volume of 
30 ml and a maximum volume of 2 x 50 ml RNAase-
free water. RNA obtained with this procedure was 
essentially free of genomic DNA. 10 ng of RNA was 
reverse transcribed and cDNA was subjected to PCR 
amplification. A quantitative reverse-transcription 
polymerase chain reaction (qRT-PCR) was performed 
using the Enhanced Avian HS RT-PCR-100 Kit 
(HSRT20, Sigma, St. Louis, MO). The reverse 
transcript (RT) reaction took place at 45°C for 50 min. 
The competition between primer sets was excluded by 
adjusting the reaction condition. Then the RT products 
went to PCR amplification directly. A first cycle of 10 
min at 95°C, 45 sec at 65°C and 1 min at 72°C was 
followed by 45 sec at 95°C, 45 sec at 65°C and 1 min at 
72°C for 25 cycles (see below). The conditions were 
chosen so that none of the RNAs analyzed reached a 
plateau at the end of the amplification protocol, i.e. they 
were in the exponential phase of amplification. Each set 
of reactions always included a no-sample negative 
control. We also performed a negative control 
containing RNA instead of cDNA to rule out genomic 
DNA contamination. The PCR products were analyzed 
on agarose gels stained with Gel Red Nucleic Acid 
Stain (Biotium, Hayward, CA). 
 
Nucleosomal ladders detection 
 
Nucleosomal ladders were revealed by a ligation-
mediated polymerase chain reaction (LMPCR). 
Genomic DNA was isolated using GenElute TM 
Mammalian Genomic DNA Miniprep Kit (Sigma, St. 
Louis, MO) according to the procedure described by 
their standard protocol. A 0.5 µg/sample of the digested 
DNA template was used. The first step is the ligation of 
dephosphorylated adaptors (120-mer and 27-mer, 
provided in the kit) to the end of the DNA fragments. 
Mixed 5 µl 10x ligation buffer, genomic 0.5 µg, adaptor 
(10X) and H2O up to 50 µl, the reaction mixture was 
heated to 55°C for 10 min; and then the adaptor 
oligonucleotides were allowed to anneal by cooling to 
10oC over 1 hour. Then 0.5 µl of T4 DNA ligase was 
added, and the reactions incubated at 16°C for 16 hours.  
DNA PCR was performed as follows: one denaturation 
cycle at 94°C for 5 min, followed by 35 cycles at 94°C 
for 1 min, 60°C for 1 min, and 72°C for 50 sec. In the 
last cycle, the products were kept at 72°C for an 
additional 5 min. One-fifth of each reaction was 
separated on a 1.5% agarose gel, stained with ethidium 
bromide and photographed. The LM-PCR was 
performed using the DNA Ladder Assay (MBI, San 
Francisco, CA). 50 μl LM-PCR reactions were prepared 
containing 1.0 µg/μl DNA from the diluted 
annealing/ligation reaction, and an additional 24 mer at 
1.25 pmol/μl, 1× Taq DNA polymerase buffer (67 mM 
Tris-HCl pH 8.8, 16.6 mM [NH4]2SO4, 0.45% Triton 
X-100, 200μg/ml gelatin, 320 μM  dATP, dTTP, dGTP, 
dCTP, 2 mM MgCl2 and 0.1 U/μl Taq polymerase as a 
Taq-antibody complex allowing a PCR hot-start. The 
Taq-antibody complex was prepared with ‘Jumpstart’ 
Taq antibody (Sigma-Aldrich, MO, USA) according to 
instructions, generating a complex at 0.83 (Taq) U/μl. 
LM-PCR reactions were heated in a DNA Engine to 
94°C for 1 min to activate Taq polymerase and remove 
12 mers, then ramped to 72°C for 10 min to re-anneal 
the target DNA and generate a complimentary sequence 
to the ligated 24 mers. PCR then proceeded over 30 
cycles at 94°C for 1 min followed by 
annealing/extension at 72°C for 2 min, then completed 
with a single 72°C for 10 min extension. 11 µl of each 
reaction was electrophoresed on a 2% agarose/EtBr gel. 
 
Proteomics - Western blot analysis 
 
Similar to our recent report ([84]), modiolus/spiral 
ganglion neuron tissue lysates were prepared in RIPA 
buffer (Pierce #89901, Thermo Scientific, Waltham, 
MA) with protease inhibitor cocktail (#78430, Thermo 
Scientific, Rockford, IL). Cells and tissue samples were 
homogenized in buffer, followed by centrifugation at 
2000 X for 10 min at 4oC. Supernatants were loaded at 
200 μg of protein/lane, after the protein concentrations 
were determined by the Bradford protein assay. Proteins 
were fractionated by SDS-PAGE gel electrophoresis 
and transferred to a PVDF blotting membrane. The blot 
was incubated with β-actin and primary antibodies for 
MCR, Bcl-2, Bax and Caspase-8 (Cell Signaling, 
Danvers, MA). The secondary antibody was horseradish 
peroxidase-conjugated goat anti-rabbit IgG (1:2000, 
Cell Signaling). 
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Statistical analyses 
 
GraphPad Prism (5.04, La Jolla, CA) was used for data 
analyses. One-way analysis of variance (ANOVA) was 
used for comparing each group such as young adults vs 
middle-aged with treatment and without treatment, for: 
BP, serum aldosterone levels, cell density, and genes 
and protein expression data. Two-way ANOVA with 
repeated measures was used to compare the ABR 
threshold shifts in the two middle-aged groups with 
treatment durations of 60 and 120 days. Bonferroni 
post-hoc tests corrected for multiple comparisons were 
used in cases where the ANOVA main effects were 
significant. Linear regression was used for measuring 
the correlations between ABR threshold shifts and cell 
density. The p<0.05 was used for the statistical 
significance criterion. 
 
ACKNOWLEDGEMENTS 
 
This work was supported by NIH Grant P01 AG009524 
from the National Institute on Aging. We appreciate 
laboratory technical assistance from Tanika Williamson 
M.S., Elliott Brecht M.S., Ashley Hinton B.S., and 
Andrea Lowe M.S.  We thank Shannon Salvog for 
project support. 
 
AUTHOR CONTRIBUTIONS 
 
RDF: Experimental design, data analysis, wrote and 
revised the article, provided project funding, project 
oversight, approved final version. BD: Experimental 
design, data collection, data analysis, wrote and revised 
the article, approved final version. XZ: Experimental 
design, data collection, data analysis, revised the article, 
approved final version. JPW: Experimental design, data 
analysis, revised the article, provided project funding, 
project oversight, approved final version. 
 
CONFLICTS OF INTEREST 
 
No financial interests of the authors represent a conflict 
of interest. One patent has been filed/pending related to 
our research reported here: 
Frisina, R.D., Walton, J.P., Ding, B., Zhu, X. (2016- 
Pending) Hormone Treatment for Age-Related Hearing 
Loss- Presbycusis. 
 
REFERENCES 
 
1. Frisina DR, Frisina RD. Speech recognition in noise 
and presbycusis: relations to possible neural 
mechanisms. Hear Res. 1997; 106:95–104. doi: 
10.1016/S0378-5955(97)00006-3 
2. Walton JP, Frisina RD, O’Neill WE. Age-related 
alteration in processing of temporal sound features 
in the auditory midbrain of the CBA mouse. J 
Neurosci. 1998; 18:2764–76. 
3. Walton JP, Simon H, Frisina RD. Age-related 
alterations in the neural coding of envelope 
periodicities. J Neurophysiol. 2002; 88:565–78. 
4. Frisina RD, Walton JP. Age-related structural and 
functional changes in the cochlear nucleus. Hear Res. 
2006; 216-217:216–23.  
doi: 10.1016/j.heares.2006.02.003 
5. Engle JR, Tinling S, Recanzone GH. Age-related 
hearing loss in rhesus monkeys is correlated with 
cochlear histopathologies. PLoS One. 2013; 
8:e55092. doi: 10.1371/journal.pone.0055092 
6. Omata Y, Tharasegaran S, Lim YM, Yamasaki Y, 
Ishigaki Y, Tatsuno T, Maruyama M, Tsuda L. 
Expression of amyloid-β in mouse cochlear hair cells 
causes an early-onset auditory defect in high-
frequency sound perception. Aging (Albany NY). 
2016; 8:427–39. doi: 10.18632/aging.100899 
7. Ding D, Jiang H, Chen GD, Longo-Guess C, Muthaiah 
VP, Tian C, Sheppard A, Salvi R, Johnson KR. N-acetyl-
cysteine prevents age-related hearing loss and the 
progressive loss of inner hair cells in γ-glutamyl 
transferase 1 deficient mice. Aging (Albany NY). 
2016; 8:730–50. doi: 10.18632/aging.100927 
8. Schuknecht HF, Gacek MR. Cochlear pathology in 
presbycusis. Ann Otol Rhinol Laryngol. 1993; 102:1–
16. 
9. Schuknecht HF. Auditory and cytocochlear correlates 
of inner ear disorders. Otolaryngol Head Neck Surg. 
1994; 110:530–38. 
10. Keithley EM, Feldman ML. Spiral ganglion cell counts 
in an age-graded series of rat cochleas. J Comp 
Neurol. 1979; 188:429–42.  
doi: 10.1002/cne.901880306 
11. Keithley EM, Ryan AF, Woolf NK. Spiral ganglion cell 
density in young and old gerbils. Hear Res. 1989; 
38:125–33. doi: 10.1016/0378-5955(89)90134-2 
12. Schmiedt RA, Lang H, Okamura HO, Schulte BA. 
Effects of furosemide applied chronically to the 
round window: a model of metabolic presbyacusis. J 
Neurosci. 2002; 22:9643–50. 
13. Schmiedt RA. Effects of aging on potassium 
homeostasis and the endocochlear potential in the 
gerbil cochlea. Hear Res. 1996; 102:125–32. doi: 
10.1016/S0378-5955(96)00154-2 
14. Schmiedt R. The Physiology of Cochlear Presbycusis. 
www.aging-us.com 2096 AGING (Albany NY) 
15. Ding B, Frisina RD, Zhu X, Sakai Y, Sokolowski B, 
Walton JP. Direct control of Na(+)-K(+)-2Cl(-)-
cotransport protein (NKCC1) expression with 
aldosterone. Am J Physiol Cell Physiol. 2014; 
306:C66–75. doi: 10.1152/ajpcell.00096.2013 
16. Gratton MA, Smyth BJ, Lam CF, Boettcher FA, 
Schmiedt RA. Decline in the endocochlear potential 
corresponds to decreased Na,K-ATPase activity in 
the lateral wall of quiet-aged gerbils. Hear Res. 1997; 
108:9–16. doi: 10.1016/S0378-5955(97)00034-8 
17. Ohlemiller KK, Dahl AR, Gagnon PM. Divergent aging 
characteristics in CBA/J and CBA/CaJ mouse 
cochleae. J Assoc Res Otolaryngol. 2010; 11:605–23. 
doi: 10.1007/s10162-010-0228-1 
18. Tadros SF, Frisina ST, Mapes F, Frisina DR, Frisina RD. 
Higher serum aldosterone correlates with lower 
hearing thresholds: a possible protective hormone 
against presbycusis. Hear Res. 2005; 209:10–18. doi: 
10.1016/j.heares.2005.05.009 
19. Trune DR, Kempton JB, Kessi M. Aldosterone 
(mineralocorticoid) equivalent to prednisolone 
(glucocorticoid) in reversing hearing loss in 
MRL/MpJ-Fas1pr autoimmune mice. Laryngoscope. 
2000; 110:1902–06. doi: 10.1097/00005537-
200011000-00025 
20. Trune DR, Kempton JB, Gross ND. Mineralocorticoid 
receptor mediates glucocorticoid treatment effects 
in the autoimmune mouse ear. Hear Res. 2006; 
212:22–32. doi: 10.1016/j.heares.2005.10.006 
21. Trune DR, Kempton JB. Aldosterone and 
prednisolone control of cochlear function in 
MRL/MpJ-Fas(lpr) autoimmune mice. Hear Res. 
2001; 155:9–20. doi: 10.1016/S0378-5955(01)00240-
4 
22. Magdich LV. [Age and the effect of 
adrenocorticotropic hormone on aldosterone 
secretion in rats]. Biull Eksp Biol Med. 1980; 89:19–
20. 
23. Hegstad R, Brown RD, Jiang NS, Kao P, Weinshilboum 
RM, Strong C, Wisgerhof M. Aging and aldosterone. 
Am J Med. 1983; 74:442–48. doi: 10.1016/0002-
9343(83)90971-3 
24. Hallengren B, Elmståhl S, Galvard H, Jerntorp P, 
Manhem P, Pessah-Rasmussen H, Stavenow L. 80-
year-old men have elevated plasma concentrations 
of catecholamines but decreased plasma renin 
activity and aldosterone as compared to young men. 
Aging (Milano). 1992; 4:341–45. 
25. Bauer JH. Age-related changes in the renin-
aldosterone system. Physiological effects and clinical 
implications. Drugs Aging. 1993; 3:238–45. doi: 
10.2165/00002512-199303030-00005 
26. Belmin J, Lévy BI, Michel JB. Changes in the renin-
angiotensin-aldosterone axis in later life. Drugs 
Aging. 1994; 5:391–400. doi: 10.2165/00002512-
199405050-00007 
27. Mulkerrin E, Epstein FH, Clark BA. Aldosterone 
responses to hyperkalemia in healthy elderly 
humans. J Am Soc Nephrol. 1995; 6:1459–62. 
28. Kau MM, Chen JJ, Wang SW, Cho WL, Wang PS. Age-
related impairment of aldosterone secretion in zona 
glomerulosa cells of ovariectomized rats. J Investig 
Med. 1999; 47:425–32. 
29. Joëls M, Karst H, DeRijk R, de Kloet ER. The coming 
out of the brain mineralocorticoid receptor. Trends 
Neurosci. 2008; 31:1–7.  
doi: 10.1016/j.tins.2007.10.005 
30. De Kloet ER, Versteeg DH, Kovacs GL. Aldosterone 
blocks the response to corticosterone in the raphe-
hippocampal serotonin system. Brain Res. 1983; 
264:323–27. doi: 10.1016/0006-8993(83)90834-X 
31. Chao HM, Ma LY, McEwen BS, Sakai RR. Regulation 
of glucocorticoid receptor and mineralocorticoid 
receptor messenger ribonucleic acids by selective 
agonists in the rat hippocampus. Endocrinology. 
1998; 139:1810–14. doi: 10.1210/endo.139.4.5896 
32. Chao HM, Sakai RR, Ma LY, McEwen BS. Adrenal 
steroid regulation of neurotrophic factor expression 
in the rat hippocampus. Endocrinology. 1998; 
139:3112–18. doi: 10.1210/endo.139.7.6114 
33. Zhu X, Ding B, Walton JP, Frisina RD. Aldosterone 
reduces spiral ganglion neuron loss in middle –aged 
CBA/CaJ mice. Assoc. Res. Otolaryngol. Abs. 2014; 
37:14. 
34. Halonen J, Hinton AS, Frisina RD, Ding B, Zhu X, 
Walton JP. Long-term treatment with aldosterone 
slows the progression of age-related hearing loss. 
Hear Res. 2016; 336:63–71.  
doi: 10.1016/j.heares.2016.05.001 
35. Müller M, von Hünerbein K, Hoidis S, Smolders JW. A 
physiological place-frequency map of the cochlea in 
the CBA/J mouse. Hear Res. 2005; 202:63–73. doi: 
10.1016/j.heares.2004.08.011 
36. Meyer AC, Frank T, Khimich D, Hoch G, Riedel D, 
Chapochnikov NM, Yarin YM, Harke B, Hell SW, 
Egner A, Moser T. Tuning of synapse number, 
structure and function in the cochlea. Nat Neurosci. 
2009; 12:444–53. doi: 10.1038/nn.2293 
37. Berger S, Wolfer DP, Selbach O, Alter H, Erdmann G, 
www.aging-us.com 2097 AGING (Albany NY) 
Reichardt HM, Chepkova AN, Welzl H, Haas HL, Lipp 
HP, Schütz G. Loss of the limbic mineralocorticoid 
receptor impairs behavioral plasticity. Proc Natl Acad 
Sci USA. 2006; 103:195–200.  
doi: 10.1073/pnas.0503878102 
38. Funder JW. Aldosterone and mineralocorticoid 
receptors in the cardiovascular system. Prog 
Cardiovasc Dis. 2010; 52:393–400.  
doi: 10.1016/j.pcad.2009.12.003 
39. Hawkins UA, Gomez-Sanchez EP, Gomez-Sanchez 
CM, Gomez-Sanchez CE. The ubiquitous mineralocor-
ticoid receptor: clinical implications. Curr Hypertens 
Rep. 2012; 14:573–80.  
doi: 10.1007/s11906-012-0297-0 
40. Latouche C, Sainte-Marie Y, Steenman M, Castro 
Chaves P, Naray-Fejes-Toth A, Fejes-Toth G, Farman 
N, Jaisser F. Molecular signature of mineralocorticoid 
receptor signaling in cardiomyocytes: from cultured 
cells to mouse heart. Endocrinology. 2010; 
151:4467–76. doi: 10.1210/en.2010-0237 
41. Lother A, Berger S, Gilsbach R, Rösner S, Ecke A, 
Barreto F, Bauersachs J, Schütz G, Hein L. Ablation of 
mineralocorticoid receptors in myocytes but not in 
fibroblasts preserves cardiac function. Hypertension. 
2011; 57:746–54.  
doi: 10.1161/HYPERTENSIONAHA.110.163287 
42. Nagata K, Obata K, Xu J, Ichihara S, Noda A, Kimata 
H, Kato T, Izawa H, Murohara T, Yokota M. 
Mineralocorticoid receptor antagonism attenuates 
cardiac hypertrophy and failure in low-aldosterone 
hypertensive rats. Hypertension. 2006; 47:656–64. 
doi: 10.1161/01.HYP.0000203772.78696.67 
43. Crochemore C, Lu J, Wu Y, Liposits Z, Sousa N, 
Holsboer F, Almeida OF. Direct targeting of 
hippocampal neurons for apoptosis by 
glucocorticoids is reversible by mineralocorticoid 
receptor activation. Mol Psychiatry. 2005; 10:790–
98. doi: 10.1038/sj.mp.4001679 
44. Tadros SF, D’Souza M, Zhu X, Frisina RD. Apoptosis-
related genes change their expression with age and 
hearing loss in the mouse cochlea. Apoptosis. 2008; 
13:1303–21. doi: 10.1007/s10495-008-0266-x 
45. Green DR. Apoptotic pathways: paper wraps stone 
blunts scissors. Cell. 2000; 102:1–4.  
doi: 10.1016/S0092-8674(00)00003-9 
46. Hengartner MO. The biochemistry of apoptosis. 
Nature. 2000; 407:770–76. doi: 10.1038/35037710 
47. Tait SW, Green DR. Mitochondria and cell death: 
outer membrane permeabilization and beyond. Nat 
Rev Mol Cell Biol. 2010; 11:621–32.  
doi: 10.1038/nrm2952 
48. Shen H, Matsui JI, Lei D, Han L, Ohlemiller KK, Bao J. 
No dramatic age-related loss of hair cells and spiral 
ganglion neurons in Bcl-2 over-expression mice or 
Bax null mice. Mol Neurodegener. 2010; 5:28. doi: 
10.1186/1750-1326-5-28 
49. Elmore S. Apoptosis: a review of programmed cell 
death. Toxicol Pathol. 2007; 35:495–516.  
doi: 10.1080/01926230701320337 
50. Staley K, Blaschke AJ, Chun J. Apoptotic DNA 
fragmentation is detected by a semi-quantitative 
ligation-mediated PCR of blunt DNA ends. Cell Death 
Differ. 1997; 4:66–75. doi: 10.1038/sj.cdd.4400207 
51. Arends MJ, Morris RG, Wyllie AH. Apoptosis. The 
role of the endonuclease. Am J Pathol. 1990; 
136:593–608. 
52. Barnes WM. PCR amplification of up to 35-kb DNA 
with high fidelity and high yield from lambda 
bacteriophage templates. Proc Natl Acad Sci USA. 
1994; 91:2216–20. doi: 10.1073/pnas.91.6.2216 
53. Wyllie AH. Glucocorticoid-induced thymocyte 
apoptosis is associated with endogenous 
endonuclease activation. Nature. 1980; 284:555–56. 
doi: 10.1038/284555a0 
54. Cheng S, Fockler C, Barnes WM, Higuchi R. Effective 
amplification of long targets from cloned inserts and 
human genomic DNA. Proc Natl Acad Sci USA. 1994; 
91:5695–99. doi: 10.1073/pnas.91.12.5695 
55. Hooker DJ, Gorry PR, Ellett AM, Wesselingh SL, 
Cherry CL. Measuring and monitoring apoptosis and 
drug toxicity in HIV patients by ligation-mediated 
polymerase chain reaction. J Cell Mol Med. 2009; 
13:948–58. doi: 10.1111/j.1582-4934.2008.00612.x 
56. Liu QY, Ribecco-Lutkiewicz M, Carson C, Testolin L, 
Bergeron D, Kohwi-Shigematsu T, Walker PR, 
Sikorska M. Mapping the initial DNA breaks in 
apoptotic Jurkat cells using ligation-mediated PCR. 
Cell Death Differ. 2003; 10:278–89.  
doi: 10.1038/sj.cdd.4401146 
57. Guinan JJ Jr. Olivocochlear efferents: anatomy, 
physiology, function, and the measurement of 
efferent effects in humans. Ear Hear. 2006; 27:589–
607. doi: 10.1097/01.aud.0000240507.83072.e7 
58. Liberman MC, Guinan JJ Jr. Feedback control of the 
auditory periphery: anti-masking effects of middle 
ear muscles vs. olivocochlear efferents. J Commun 
Disord. 1998; 31:471–82. doi: 10.1016/S0021-
9924(98)00019-7 
59. Kim  S,  Frisina  DR,  Frisina  RD.  Effects  of  age  on   
www.aging-us.com 2098 AGING (Albany NY) 
contralateral suppression of distortion product 
otoacoustic emissions in human listeners with 
normal hearing. Audiol Neurootol. 2002; 7:348–57. 
doi: 10.1159/000066159 
60. Frisina RD, Newman SR, Zhu X. Auditory efferent 
activation in CBA mice exceeds that of C57s for 
varying levels of noise. J Acoust Soc Am. 2007; 
121:EL29–34. doi: 10.1121/1.2401226 
61. Jacobson M, Kim S, Romney J, Zhu X, Frisina RD. 
Contralateral suppression of distortion-product 
otoacoustic emissions declines with age: a 
comparison of findings in CBA mice with human 
listeners. Laryngoscope. 2003; 113:1707–13. doi: 
10.1097/00005537-200310000-00009 
62. Zhu X, Vasilyeva ON, Kim S, Jacobson M, Romney J, 
Waterman MS, Tuttle D, Frisina RD. Auditory 
efferent feedback system deficits precede age-
related hearing loss: contralateral suppression of 
otoacoustic emissions in mice. J Comp Neurol. 2007; 
503:593–604. doi: 10.1002/cne.21402 
63. Fitzgibbons PJ, Gordon-Salant S. Age-related 
differences in discrimination of temporal intervals in 
accented tone sequences. Hear Res. 2010; 264:41–
47. doi: 10.1016/j.heares.2009.11.008 
64. Hall JW, Buss E, Grose JH, Roush PA. Effects of age 
and hearing impairment on the ability to benefit 
from temporal and spectral modulation. Ear Hear. 
2012; 33:340–48.  
doi: 10.1097/AUD.0b013e31823fa4c3 
65. Snell KB, Mapes FM, Hickman ED, Frisina DR. Word 
recognition in competing babble and the effects of 
age, temporal processing, and absolute sensitivity. J 
Acoust Soc Am. 2002; 112:720–27.  
doi: 10.1121/1.1487841 
66. Leong UC, Barsz K, Allen PD, Walton JP. Neural 
correlates of age-related declines in frequency 
selectivity in the auditory midbrain. Neurobiol Aging. 
2011; 32:168–78.  
doi: 10.1016/j.neurobiolaging.2009.01.006 
67. Williamson TT, Zhu X, Walton JP, Frisina RD. Auditory 
brainstem gap responses start to decline in mice in 
middle age: a novel physiological biomarker for age-
related hearing loss. Cell Tissue Res. 2015; 361:359–
69. doi: 10.1007/s00441-014-2003-9 
68. Guimaraes P, Zhu X, Cannon T, Kim S, Frisina RD. Sex 
differences in distortion product otoacoustic 
emissions as a function of age in CBA mice. Hear Res. 
2004; 192:83–89. doi: 10.1016/j.heares.2004.01.013 
69. Zettel ML, Zhu X, O’Neill WE, Frisina RD. Age-related 
decline in Kv3.1b expression in the mouse auditory 
brainstem correlates with functional deficits in the 
medial olivocochlear efferent system. J Assoc Res 
Otolaryngol. 2007; 8:280–93. doi: 10.1007/s10162-
007-0075-x 
70. Alam SA, Oshima T, Suzuki M, Kawase T, Takasaka T, 
Ikeda K. The expression of apoptosis-related proteins 
in the aged cochlea of Mongolian gerbils. 
Laryngoscope. 2001; 111:528–34.  
doi: 10.1097/00005537-200103000-00026 
71. Nevado J, Sanz R, Casqueiro JC, Ayala A, García-
Berrocal JR, Ramírez-Camacho R. Ageing evokes an 
intrinsic pro-apoptotic signalling pathway in rat 
cochlea. Acta Otolaryngol. 2006; 126:1134–39. doi: 
10.1080/00016480600672592 
72. Jókay I, Soós G, Répássy G, Dezsõ B. Apoptosis in the 
human inner ear. Detection by in situ end-labeling of 
fragmented DNA and correlation with other markers. 
Hear Res. 1998; 117:131–39. 
73. Someya S, Yamasoba T, Weindruch R, Prolla TA, 
Tanokura M. Caloric restriction suppresses apoptotic 
cell death in the mammalian cochlea and leads to 
prevention of presbycusis. Neurobiol Aging. 2007; 
28:1613–22.  
doi: 10.1016/j.neurobiolaging.2006.06.024 
74. Usami S, Takumi Y, Fujita S, Shinkawa H, Hosokawa 
M. Cell death in the inner ear associated with aging 
is apoptosis? Brain Res. 1997; 747:147–50. doi: 
10.1016/S0006-8993(96)01243-7 
75. Garrity MM, Burgart LJ, Riehle DL, Hill EM, Sebo TJ, 
Witzig T. Identifying and quantifying apoptosis: 
navigating technical pitfalls. Mod Pathol. 2003; 
16:389–94.  
doi: 10.1097/01.MP.0000062657.30170.92 
76. Lawrence MD, Blyth BJ, Ormsby RJ, Tilley WD, Sykes 
PJ. False-positive TUNEL staining observed in SV40 
based transgenic murine prostate cancer models. 
Transgenic Res. 2013; 22:1037–47.  
doi: 10.1007/s11248-013-9694-7 
77. Negoescu A, Lorimier P, Labat-Moleur F, Drouet C, 
Robert C, Guillermet C, Brambilla C, Brambilla E. In 
situ apoptotic cell labeling by the TUNEL method: 
improvement and evaluation on cell preparations. J 
Histochem Cytochem. 1996; 44:959–68. doi: 
10.1177/44.9.8773561 
78. Takahashi K, Kamiya K, Urase K, Suga M, Takizawa T, 
Mori H, Yoshikawa Y, Ichimura K, Kuida K, Momoi T. 
Caspase-3-deficiency induces hyperplasia of 
supporting cells and degeneration of sensory cells 
resulting in the hearing loss. Brain Res. 2001; 
894:359–67. doi: 10.1016/S0006-8993(01)02123-0 
www.aging-us.com 2099 AGING (Albany NY) 
79. Kwon DN, Park WJ, Choi YJ, Gurunathan S, Kim JH. 
Oxidative stress and ROS metabolism via down-
regulation of sirtuin 3 expression in Cmah-null mice 
affect hearing loss. Aging (Albany NY). 2015; 7:579–
94. doi: 10.18632/aging.100800 
80. Borkholder DA, Zhu X, Frisina RD. Round window 
membrane intracochlear drug delivery enhanced by 
induced advection. J Control Release. 2014; 
174:171–76. doi: 10.1016/j.jconrel.2013.11.021 
81.  orkholder DA, Zhu X, Hyatt BT, Archilla AS, Livingston 
WJ 3rd, Frisina RD. Murine intracochlear drug 
delivery: reducing concentration gradients within the 
cochlea. Hear Res. 2010; 268:2–11. doi: 
10.1016/j.heares.2010.04.014 
82. Johnson DG, Frisina RD, Borkholder DA. In-plane 
biocompatible microfluidic interconnects for 
implantable microsystems. IEEE Trans Biomed Eng. 
2011; 58:943–48. doi: 10.1109/TBME.2010.2098031 
83. Johnson DG, Waldron MJ, Frisina RD, Borkholder DA. 
Implantable micropump technologies for murine 
intracochlear infusions. Conf Proc IEEE Eng Med Biol 
Soc. 2010; 2010:6441-6444.  
doi: 10.1109/IEMBS.2010.5627335. 
84. Tang X, Zhu X, Ding B, Walton JP, Frisina RD, Su J. 
Age-related hearing loss: GABA, nicotinic 
acetylcholine and NMDA receptor expression 
changes in spiral ganglion neurons of the mouse. 
Neuroscience. 2014; 259:184–93.  
doi: 10.1016/j.neuroscience.2013.11.058 
85. Marone M, Mozzetti S, De Ritis D, Pierelli L, Scambia 
G. Semiquantitative RT-PCR analysis to assess the 
expression levels of multiple transcripts from the 
same sample. Biol Proced Online. 2001; 3:19–25. 
doi: 10.1251/bpo20. 
 
